Evidence map›Paper›PMID 23599311›Full record

ArticleThe Journal of infectious diseases2013

Using ultradeep pyrosequencing to study HIV-1 coreceptor usage in primary and dual infection.

Gabriel A Wagner, Mary E Pacold, Edgar Vigil, Gemma Caballero, Sheldon R Morris, Sergei L Kosakovsky Pond, Susan J Little, Douglas D Richman, Sara Gianella, Davey M Smith

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of infectious diseases, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.5field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Observational
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Gabriel A WagnerUniversity of California San Diego, La Jolla, CA 92093, USA. gawagner@ucsd.edu
Mary E Pacold
Edgar Vigil
Gemma Caballero
Sheldon R Morris
Sergei L Kosakovsky Pond
Susan J Little
Douglas D Richman
Sara Gianella
Davey M Smith
University of California, San Diego · USVA San Diego Healthcare System · USThermo Fisher Scientific (Norway) · NO

Funding

VirologyP30AI036214 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Maile Ann Young Karris · 1994 to 2026
$78.4M
UCSD Department of Medicine HIV/AIDS Clinical Trials UnitUM1AI069432 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI TIMOTHY J. WILKIN · 2012 to 2026
$50.4M
STRUCTURAL NEUROIMAGING COREP30MH062512 · NIMH · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI DAVID J MOORE · 2001 to 2026
$50.4M
Using NK Cells to eliminate the latent HIV reservoirU19AI096113 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI LUCIW, PAUL · 2011 to 2015
$39.5M
Transmission ProbabilityP01AI074621 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI LITTLE, SUSAN JANET · 2008 to 2012
$23.1M
Primary Infection Resource Consortium (PIRC)R24AI106039 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI LITTLE, SUSAN JANET · 2013 to 2021
$23.1M
Southern California Primary Infection ProgramU01AI043638 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI RICHMAN, DOUGLAS D · 1998 to 2010
$21.3M
UCSD Department of Medicine HIV/AIDS Clinical Trials UnitU01AI069432 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI BENSON, CONSTANCE ANN · 2007 to 2011
$19.3M
HOPE Training GrantT32AI007384 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Sara Gianella Weibel, Scott L Letendre · 1990 to 2026
$9.7M
Viral correlates of neutralizing antibody responseU19AI090970 · NIAID · INTERNATIONAL AIDS VACCINE INITIATIVE · PI POIGNARD, PASCAL · 2010 to 2014
$9.3M
The Universidade Eduardo Mondlane/UCSD Medical Education PartnershipR24TW008908 · FIC · EDUARDO MONDLANE UNIVERSITY · PI NOORMAHOMED, EMILIA VIRGINIA · 2010 to 2015
$9.0M
Molecular Epidemiology for HIV Prevention for Drug Users and Other Risk Groups DP1DA034978 · NIDA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SMITH, DAVID MITCHELL · 2012 to 2016
$4.1M
FIC NIH HHS R24 TW008908FIC NIH HHS TW008908NIAID NIH HHS AI080353NIAID NIH HHS AI090970NIAID NIH HHS AI096113NIAID NIH HHS AI100665NIAID NIH HHS AI36214NIAID NIH HHS AI43638NIAID NIH HHS AI47745NIAID NIH HHS AI69432NIAID NIH HHS AI74621NIAID NIH HHS K24 AI100665NIAID NIH HHS P01 AI074621NIAID NIH HHS P30 AI036214NIAID NIH HHS R01 AI047745NIAID NIH HHS R21 AI047745NIAID NIH HHS R21 AI080353NIAID NIH HHS R24 AI106039NIAID NIH HHS R56 AI047745NIAID NIH HHS T32 AI007384NIAID NIH HHS U01 AI043638NIAID NIH HHS U01 AI069432NIAID NIH HHS U19 AI090970NIAID NIH HHS U19 AI096113NIAID NIH HHS UM1 AI069432NIDA NIH HHS DA034978NIDA NIH HHS DP1 DA034978NIGMS NIH HHS GM093939NIGMS NIH HHS R01 GM093939NIMH NIH HHS MH097520NIMH NIH HHS MH62512NIMH NIH HHS MH83552NIMH NIH HHS P30 MH062512NIMH NIH HHS R01 MH083552NIMH NIH HHS R01 MH097520
6 · The paper itself

Abstract

HIV-1 dual infection (DI) and CXCR4 (X4) coreceptor usage are associated with accelerated disease progression but frequency and dynamics of coreceptor usage during DI is unknown. Ultradeep sequencing was used to interrogate for DI and infer coreceptor usage in longitudinal blood samples of 102 subjects. At baseline, X4 usage was high (23 subjects harbored X4 variants) and was not associated with infection duration or DI. Coreceptor usage changed over time in 12 of 47 participants, and X4 usage emerged in 4 of 41 monoinfections vs 2 of 5 superinfections (P = .12), suggesting a weak statistical trend toward occurrence of superinfection and acquiring X4 usage.

Indexed as

AdultHIV-1HIV InfectionsHumansMaleReceptors, CXCR4Sequence Analysis, DNAReceptors, CXCR4coreceptor tropismcoreceptor usagegenotypic coreceptor usage predictiongenotypic tropism predictionHIV-1 coinfectionHIV-1 dual infectionHIV-1 superinfectionnext-generation sequencingultradeep pyrosequencing

Identifiers

PMID23599311
PMCPMC3685231
OpenAlexW2135642826

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.